Bristol-Myers Squibb GmbH & Co.KG aA

vorige Seite Seite 1 von 3 nächste Seite

Bristol-Myers Squibb-Sponsored Partnering for Cure(TM) Programme Announces New Winning Projects Designed to Investigate Novel Ways to Cure Viral Diseases

The Partnering for Cure faculty of experts today announced the four recipients of awards for research proposals that will help to provide insights into the pathophysiology of viral diseases and the …

OTE0004
11.11.2014 13:52
 

SHE Day: The Strong, HIV Positive, Empowered Women (SHE) Faculty and Bristol-Myers Squibb Celebrated Four Years of SHE, a First-of-Its Kind Programme Addressing the Specific Challenges Faced by Women Living with HIV in Europe

'SHE' (Strong, HIV positive, Empowered Women) experts and Bristol-Myers Squibb hosted on Friday, 27 June a 'SHE Day' in Paris, a yearly meeting that brings together a diverse group of experts including …

OTE0003
30.06.2014 10:04
 
OTE0007
08.04.2014 11:11
 

Bristol-Myers Squibb-Sponsored Partnering for Cure(TM) Program Names Three European Award Winners for Research Projects Focused on Cure in Viral Diseases

First-ever, Europe-wide scientific initiative designed to accelerate virology clinical research & transform clinical outcomes for patients

OTE0002
31.01.2014 08:04
 

YERVOY®(ipilimumab) Receives Marketing Authorisation for First-Line Treatment of Adult Patients with Advanced Melanoma in Europe

Yervoy, an innovative immuno-oncology therapy that has demonstrated durable long-term survival in some patients,[1],[2] is now approved for use in previously-untreated patients

OTE0003
08.11.2013 09:04
 

Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analysis of Yervoy(TM) (Ipilimumab) Treatment in More Than 1,800 Patients with Metastatic or Locally Advanced or Unresectable Melanoma

Bristol-Myers Squibb Company today announced results from a pooled analysis of survival data for 12 studies (n=1,861) in patients with metastatic or locally advanced or unresectable melanoma who were …

OTE0001
28.09.2013 00:13
 

High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection

Bristol-Myers Squibb Company [http://www.bms.com ] today announced additional, interim Phase II data demonstrating that 12- and 24-week Triple DAA treatment regimens of daclatasvir (DCV), asunaprevir (ASV) …

OTE0003
23.04.2013 12:39
 
OTE0009
07.12.2012 18:01
 

Subcutaneous Formulation of ORENCIA® (abatacept) Approved by European Commission

Proven biologic is first therapy available in both subcutaneous and intravenous formulations for adults with moderate to severe active rheumatoid arthritis

OTE0005
05.10.2012 17:03
 

New Four- and Five-Year Survival Data for YERVOY® (ipilimumab) in Treatment-Naïve and Previously-Treated Metastatic Melanoma Presented at the ESMO 2012 Congress (European Society for Medical Oncology)

Bristol-Myers Squibb Company today announced four- and five-year survival rates based on long-term follow up from Phase 3 and Phase 2 YERVOY(R) (ipilimumab) clinical trials in patients with treatment-naïve …

OTE0001
29.09.2012 13:04
 

Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress

Bristol-Myers Squibb Company [http://www.bms.com ] today announced that the company will present 18 abstracts on abatacept at the European League Against Rheumatism (EULAR) Annual European Congress of …

OTE0007
14.05.2012 14:04
 

European Commission Approves Labelling Update for REYATAZ® (atazanavir sulfate) in Pregnant Women Living With HIV

Bristol-Myers Squibb Company today announced that the European Commission approved a labelling update for REYATAZ(R) (atazanavir sulfate) based on new data generated in pregnant women living with HIV.

OTE0013
25.11.2011 17:54
 
vorige Seite nächste Seite